Benign Prostatic Hyperplasia Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Allergan PLC, Eli Lilly, Merck, Astellas Pharma, GlaxoSmithKline

Benign Prostatic Hyperplasia Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Allergan PLC, Eli Lilly, Merck, Astellas Pharma, GlaxoSmithKline
DelveInsight’s “Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Benign Prostatic Hyperplasia, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Benign Prostatic Hyperplasia, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Benign Prostatic Hyperplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Benign Prostatic Hyperplasia Market Forecast

 

Some of the key facts of the Benign Prostatic Hyperplasia Market Report: 

  • The Benign Prostatic Hyperplasia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to a study by Boyle et al. (n.d.), up to 60% of men over 60 may have hypertension, and 50% of men over 60 may have symptoms consistent with Benign Prostatic Hyperplasia
  • The most anticipated new treatments are Vibegron (Urovant Sciences) and DKF-313 (Dongkook Pharmaceutical), which are waiting for approval. In a phase II clinical trial, the novel medication AUS-131 from Ausio Pharmaceuticals was examined
  • Key Benign Prostatic Hyperplasia Companies: Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Astellas Pharma Inc., GlaxoSmithKline, Dongkook Pharma, RECORDATI GROUP, Eli Lilly and Company, Sophiris Bio Corp, JW Pharmaceutical, Sophiris Bio Corp, Warner Chilcott, Materia Medica Holding, Ausio Pharma, Nymox Corporation, QLT Inc., Spectrum Pharma, GemVax & Kael, AEterna Zentaris, Amgen, and others
  • Key Benign Prostatic Hyperplasia Therapies: GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Silodosin, Levitra (Vardenafil, BAY38-9456), PRX302, WC3055, Afalaza, S-equol, NX-1207, QLT0074, Tamsulosin, Ozarelix, GV1001, Cetrorelix, botulinum toxin Type A, and others
  • The Benign Prostatic Hyperplasia epidemiology based on gender analyzed that Benign Prostatic Hyperplasia is more common in older males as compared to those below 40 years
  • The Benign Prostatic Hyperplasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Benign Prostatic Hyperplasia pipeline products will significantly revolutionize the Benign Prostatic Hyperplasia market dynamics.

 

Benign Prostatic Hyperplasia Overview

Men who have Benign Prostatic Hyperplasia, also known as benign prostatic hyperplasia, have enlarged prostates that are not malignant. Other names for benign prostatic hyperplasia are benign prostatic blockage and benign prostatic hypertrophy. The urethra is pinched and pressed against by the prostate as it grows in size. the bladder wall thickens

 

Get a Free sample for the Benign Prostatic Hyperplasia Market Report 

https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-market

 

Benign Prostatic Hyperplasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Benign Prostatic Hyperplasia Epidemiology Segmentation:

The Benign Prostatic Hyperplasia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Benign Prostatic Hyperplasia
  • Prevalent Cases of Benign Prostatic Hyperplasia by severity
  • Gender-specific Prevalence of Benign Prostatic Hyperplasia
  • Diagnosed Cases of Episodic and Chronic Benign Prostatic Hyperplasia

 

Download the report to understand which factors are driving Benign Prostatic Hyperplasia epidemiology trends @ Benign Prostatic Hyperplasia Epidemiology Forecast

 

Benign Prostatic Hyperplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Benign Prostatic Hyperplasia market or expected to get launched during the study period. The analysis covers Benign Prostatic Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Benign Prostatic Hyperplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Benign Prostatic Hyperplasia Therapies and Key Companies

  • DKF0313: Dongkook Pharmaceutical
  • Vibegron: Urovant Sciences
  • AUS-131 (S-equo): Ausio Pharmaceuticals

 

Discover more about therapies set to grab major Benign Prostatic Hyperplasia market share @ Benign Prostatic Hyperplasia Treatment Market

 

Scope of the Benign Prostatic Hyperplasia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Benign Prostatic Hyperplasia Companies: Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Astellas Pharma Inc., GlaxoSmithKline, Dongkook Pharma, RECORDATI GROUP, Eli Lilly and Company, Sophiris Bio Corp, JW Pharmaceutical, Sophiris Bio Corp, Warner Chilcott, Materia Medica Holding, Ausio Pharma, Nymox Corporation, QLT Inc., Spectrum Pharma, GemVax & Kael, AEterna Zentaris, Amgen, and others
  • Key Benign Prostatic Hyperplasia Therapies: GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Silodosin, Levitra (Vardenafil, BAY38-9456), PRX302, WC3055, Afalaza, S-equol, NX-1207, QLT0074, Tamsulosin, Ozarelix, GV1001, Cetrorelix, botulinum toxin Type A, and others
  • Benign Prostatic Hyperplasia Therapeutic Assessment: Benign Prostatic Hyperplasia current marketed and Benign Prostatic Hyperplasia emerging therapies
  • Benign Prostatic Hyperplasia Market Dynamics: Benign Prostatic Hyperplasia market drivers and Benign Prostatic Hyperplasia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Benign Prostatic Hyperplasia Unmet Needs, KOL’s views, Analyst’s views, Benign Prostatic Hyperplasia Market Access and Reimbursement 

 

To know more about Benign Prostatic Hyperplasia companies working in the treatment market, visit @ Benign Prostatic Hyperplasia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Benign Prostatic Hyperplasia Market Report Introduction

2. Executive Summary for Benign Prostatic Hyperplasia

3. SWOT analysis of Benign Prostatic Hyperplasia

4. Benign Prostatic Hyperplasia Patient Share (%) Overview at a Glance

5. Benign Prostatic Hyperplasia Market Overview at a Glance

6. Benign Prostatic Hyperplasia Disease Background and Overview

7. Benign Prostatic Hyperplasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Benign Prostatic Hyperplasia 

9. Benign Prostatic Hyperplasia Current Treatment and Medical Practices

10. Benign Prostatic Hyperplasia Unmet Needs

11. Benign Prostatic Hyperplasia Emerging Therapies

12. Benign Prostatic Hyperplasia Market Outlook

13. Country-Wise Benign Prostatic Hyperplasia Market Analysis (2019–2032)

14. Benign Prostatic Hyperplasia Market Access and Reimbursement of Therapies

15. Benign Prostatic Hyperplasia Market Drivers

16. Benign Prostatic Hyperplasia Market Barriers

17.  Benign Prostatic Hyperplasia Appendix

18. Benign Prostatic Hyperplasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services